Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 2/20 | 0.31 |
| ▸ | CES1 | P23141 | 2/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30934037 | 1.00 | ALDH1A1 (0.43) | ALDH1A1ALOX15NAPRTCES2CES1 | |
| SCHEMBL27886904 | 0.81 | GPR27 (0.43) | ALDH1A1ALOX15NAPRTKEAP1NFE2L2 | |
| SCHEMBL445478 | 0.80 | NAPRT (0.50) | ALDH1A1ALOX15NAPRTKEAP1NFE2L2 | |
| SCHEMBL29551348 | 0.80 | NAPRT (0.50) | ALDH1A1ALOX15NAPRTKEAP1NFE2L2 | |
| Hydrochloric Acid SCHEMBL2211447 | 0.78 | NAPRT (0.48) | ALDH1A1ALOX15NAPRTKEAP1NFE2L2 | |
| SCHEMBL2762235 | 0.78 | DGAT1 (0.42) | ALDH1A1NPC1RAB9A | |
| SCHEMBL30641935 | 0.78 | DGAT1 (0.42) | ALDH1A1NPC1RAB9A | |
| SCHEMBL3160278 | 0.78 | SMN1; SMN2 (0.40) | ALDH1A1ALOX15NAPRTCES2CES1 | |
| SCHEMBL30506330 | 0.78 | SMN1; SMN2 (0.40) | ALDH1A1ALOX15NAPRTCES2CES1 | |
| SCHEMBL3959784 | 0.78 | ALDH1A1 (0.43) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658074-A1 | FUNGICIDAL COMPOSITIONS | Syngenta Crop Protection AG (CH) | 2025-12-10 | — | — | EP | disclosed |
| EP-4655284-A1 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2025-12-03 | — | — | EP | disclosed |
| EP-4626232-A1 | FUNGICIDAL COMPOSITIONS | Syngenta Crop Protection AG (CH) | 2025-10-08 | — | — | EP | disclosed |
| EP-4619396-A1 | MICROBIOCIDAL TETRAHYDROISOQUINOLINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2025-09-24 | — | — | EP | disclosed |
| WO-2024160801-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA CROP PROTECTION AG (CH) | 2024-08-08 | — | — | WO | disclosed |
| WO-2024156886-A1 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024115546-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024115546-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024105104-A1 | MICROBIOCIDAL TETRAHYDROISOQUINOLINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-05-23 | — | — | WO | disclosed |
| CN-116987076-A | 1,2, 4-triazolo [4,3-a ] pyridine sulfone derivative, and preparation method and application thereof | 贵州大学 | 2023-11-03 | — | — | CN | disclosed |
| EP-1699767-A2 | PROCESS FOR THE PREPARATION OF PYRIDOPYRIMIDONES | Scios, Inc. (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | CHEN GUOQING | 2006-02-23 | — | — | US | disclosed |
| US-6995162-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2005-11-24 | — | — | US | disclosed |
| CN-1671700-A | Substituted alkylamine derivatives and methods of use | AMGEN INC (US) | 2005-09-21 | — | — | CN | disclosed |
| US-20050176957-A1 | Process for the preparation of pyridopyrimidones | SCIOS INC. | 2005-08-11 | — | — | US | disclosed |
| WO-2005065416-A2 | PROCESS FOR THE PREPARATION OF PYRIDOPYRIMIDONES | SCIOS INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | ALDH1A1 389/4885ALOX15 347/4885NAPRT 234/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | ALDH1A1 261/4885ALOX15 229/4885NAPRT 213/4885 |
| US-20050176957-A1 | Process for the preparation of pyridopyrimidones | PDXK, PNPO, AGPS | ALDH1A1 1829/4885ALOX15 1911/4885NAPRT 136/4885 |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | ALDH1A1 389/4885ALOX15 347/4885NAPRT 234/4885 |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | ALDH1A1 261/4885ALOX15 229/4885NAPRT 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.